Halozyme Therapeutics: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported fourth-quarter net income of $73.2 million, after reporting a loss in the same period a year earlier.

The San Diego-based company said it had net income of 50 cents per share.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 56 cents per share.

The biopharmaceutical company posted revenue of $121.7 million in the period, beating Street forecasts. Three analysts surveyed by Zacks expected $119.7 million.

For the year, the company reported net income of $129.1 million, or 91 cents per share, swinging to a profit in the period. Revenue was reported as $267.6 million.

Halozyme Therapeutics expects full-year earnings to be $1.40 to $1.55 per share, with revenue in the range of $375 million to $395 million.

Halozyme Therapeutics shares have climbed 11% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $47.21, more than doubling in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALO